Analyst Price Targets — CASIF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2024 7:22 am | Sean Lee | H.C. Wainwright | $6.00 | $3.26 | StreetInsider | CASI Pharmaceuticals (CASI) PT Lowered to $6 at H.C. Wainwright |
| August 15, 2022 10:29 am | — | H.C. Wainwright | $12.00 | $4.02 | Benzinga | HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Adjusts PT to $12 (1-for-10 reverse stock split) |
Latest News for CASIF
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel (the "Panel") of The Nasdaq…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CASIF.
U.S. House Trading
No House trades found for CASIF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.